메르켈세포암(MCC) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Merkel Cell Carcinoma (MCC) Market Outlook

Thelansis's "Merkel Cell Carcinoma (MCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Merkel Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Merkel Cell Carcinoma (MCC) Overview

Merkel Cell Carcinoma is an aggressive neuroendocrine skin malignancy arising from mechanoreceptor cells, strongly linked to Merkel cell polyomavirus and UV-induced immunosuppression. It typically presents as a firm, painless, flesh-colored or violaceous nodule on sun-exposed skin in elderly or immunocompromised patients. Diagnosis involves excisional biopsy with CK20 and synaptophysin immunostaining; nodal involvement and distant metastasis define severity. Surgery with sentinel lymph node biopsy forms the primary approach, with adjuvant radiotherapy for locoregional control. PD-1/PD-L1 checkpoint inhibitors are first-line for advanced disease. Surveillance imaging monitors recurrence. Prognosis worsens significantly with metastasis; early detection and multidisciplinary care are essential.

Key Highlights

• In Germany, the diagnosed MCC patient pool is projected to increase from approximately 315 cases in 2025 to 335 cases by 2035.
• MCC remains a rare but highly aggressive neuroendocrine skin cancer with significant mortality risk.
• Increasing incidence is linked to aging populations and greater exposure to risk factors including immunosuppression.
• Immunotherapy has transformed treatment outcomes in advanced disease settings.
• Early detection and multidisciplinary management remain critical to improving survival.

Market Overview

• The Germany MCC market is projected to grow from approximately $180 MN in 2025 to $360 MN by 2035.
• Market growth is supported by:
• Increasing utilization of immune checkpoint inhibitors
• Expansion of treatment options for advanced and recurrent disease
• Market value growth is driven by premium oncology therapies and longer treatment duration.
• Future growth will depend on next-generation immunotherapies and combination treatment strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Incyte Corporation
• Fujifilm Pharmaceuticals U.S.A., Inc.
• Replimune, Inc.
• Phio Pharmaceuticals Inc.
• Sotio Biotech Inc.
• Kupando GmbH
• AstraZeneca
• Checkpoint Therapeutics, Inc.
• ImmunityBio, Inc.
• KaliVir Immunotherapeutics
• Neonc Technologies, Inc.
• SystImmune Inc.
• Medicenna Therapeutics, Inc.
• Sensei Biotherapeutics, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)